Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,092 across all filing types
Latest filing 2024-09-16 Director's Dealing
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-09-16 English
Director's Dealing 2024
Director's Dealing
2024-09-12 English
Board/Management Information 2024
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 11, 2024, by AIM Immunotech Inc. It reports amendments to employment agreements of the CEO and another officer, specifically changes in compensation arrangements. The content focuses on management compensation changes and employment agreement amendments, which are typical disclosures related to changes in senior management or board members. There are no financial statements or detailed financial performance data included, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy solicitation, voting results, or a merger announcement. The primary subject is changes in management compensation and employment terms, which fits the category of Board/Management Information (MANG). The document length is about 5104 characters, which is sufficient for a substantive filing rather than a brief announcement. Therefore, the best classification is MANG with high confidence.
2024-09-12 English
SC 13D/A
Major Shareholding Notification
2024-09-11 English
SC 13D/A
Major Shareholding Notification
2024-09-03 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q2 2024
2024-08-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.